Exenatide: all 231 studies that test it
Page 2 of 3. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Exenatide For Reducing the Reinforcing Effects of CocaineWithdrawnNCT06252623Phase 1
- Assessment of Safety, Tolerability and Drug Levels of Exenatide ImplantCompletedNCT05670379Phase 1
- Exenatide for Smoking Cessation and Prevention of Weight GainCompletedNCT05610800Phase 2
- Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)CompletedNCT04897802Phase 4
- Brain Activation and Satiety in Children 2Active, not recruitingNCT04520490Phase 3
- Exenatide Treatment in Parkinson's DiseaseStatus unknownNCT04305002Phase 2
- Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's DiseaseCompletedNCT04232969Phase 3
- Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS PatientsStatus unknownNCT04029272Phase 4
- Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.CompletedNCT03970044Phase 4
- Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male VolunteersCompletedNCT03835013Not applicable
- Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese PatientsStatus unknownNCT03671733Phase 3
- Effects of Exenatide on Motor Function and the BrainCompletedNCT03456687Phase 1
- Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 DiabetesStatus unknownNCT03444142Phase 4
- Research of Intensive Metabolic Intervention Before Pregnancy in PCOSStatus unknownNCT03383068Phase 4
- DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2CompletedNCT03361098Phase 4
- Research of Exenatide for Overweight/Obese PCOS Patients With IGRCompletedNCT03352869Phase 4
- Trial of EXenatide in Acute Ischaemic StrokeStatus unknownNCT03287076Phase 2
- Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?CompletedNCT03232112Phase 2
- Effect of Exenatide on Cortisol SecretionCompletedNCT03160261Phase 4
- A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or ObeseStatus unknownNCT03018665Phase 4
- Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic CasesCompletedNCT03017352Phase 2
- Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.CompletedNCT03007329Phase 4
- Exenatide and Brown Adipose TissueStatus unknownNCT03002675Phase 4
- Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DMStatus unknownNCT02887625Not applicable
- Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma TherapyCompletedNCT02860923Phase 3
- Long-acting Exenatide and Cognitive Decline in Dysglycemic PatientsStatus unknownNCT02847403Phase 3
- The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke VolunteersCompletedNCT02838589Phase 2
- The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in StrokeStatus unknownNCT02829502Phase 2
- Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 DiabetesWithdrawnNCT02811484Phase 4
- Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMICompletedNCT02794402Phase 2
- Exenatide and Impaired Hypoglycaemic Awareness in Type 1 DiabetesCompletedNCT02735031Phase 2/3
- Gut Hormones in Obesity, Nicotine and Alcohol DependenceStatus unknownNCT02690987Early Phase 1
- Effect of Exenatide on 24h-UAER in Patients With Diabetic NephropathyCompletedNCT02690883Phase 4
- Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic HypoglycemiaCompletedNCT02685852Phase 1
- GLP-1 and Hyperoxia for Organ Protection in Heart SurgeryActive, not recruitingNCT02673931Not applicable
- Study of the Effects of Intravenous Exenatide on Cardiac RepolarizationCompletedNCT02650479Phase 1
- Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes SubjectsCompletedNCT02621489Phase 4
- Diabetes Islet Preservation Immune TreatmentWithdrawnNCT02586831Phase 1/2
- The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying RateStatus unknownNCT02584582Phase 2/3
- Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial FunctionStatus unknownNCT02584075Phase 4
- Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DMCompletedNCT02467920Phase 4
- Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 DiabetesCompletedNCT02449603Phase 4
- GLP-1 Analogs for Neuroprotection After Cardiac ArrestCompletedNCT02442791Not applicable
- Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery PatientsCompletedNCT02432976Phase 2/3
- COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI TrialCompletedNCT02404376Phase 3
- Exenatide Once Weekly, Cardiovascular Risk and Type-2 DiabetesCompletedNCT02380521Phase 4
- Autoinjector Device Assessment StudyCompletedNCT02349802Phase 1
- Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure PatientsStatus unknownNCT02344641Not applicable
- A Comparison of Exenatide and Insulin GlargineCompletedNCT02325960Phase 4
- Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal SubjectsCompletedNCT02320045Phase 1
- Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body WeightCompletedNCT02313220Phase 2
- Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 DiabetesCompletedNCT02303730Phase 4
- Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)CompletedNCT02194595Phase 3
- GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity MenCompletedNCT02170324Phase 4
- Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes MellitusStatus unknownNCT02162550Phase 4
- Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential TherapyStatus unknownNCT02129985Phase 4
- Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory StatusStatus unknownNCT02118376Not applicable
- Safety Evaluation of Adverse Reactions in DiabetesCompletedNCT02092597Phase 4
- Exenatide and Weight Loss for Diabetes PreventionCompletedNCT02084654Phase 1
- Trial of Exenatide for Parkinson's DiseaseCompletedNCT01971242Phase 2
- Exenatide for Stress HyperglycemiaCompletedNCT01969149Phase 2/3
- Exenatide for Myocardial Protection During Reperfusion StudyStatus unknownNCT01938235Phase 2
- An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes MellitusCompletedNCT01876849Phase 3
- Feasibility Study of Exenatide by Continuous Subcutaneous InfusionCompletedNCT01857895Phase 1
- Study of the Acute Metabolic Effect of Exenatide in Type 1 DiabetesCompletedNCT01855490Phase 1
- A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.CompletedNCT01843127Phase 1
- Exenatide on GI Motor Function and Permeability in Short Bowel SyndromeWithdrawnNCT01818648Phase 4
- Treatment of Antipsychotic-associated Obesity With a GLP-1 AnalogueCompletedNCT01794429Phase 3
- Extension Study for 2993-112CompletedNCT01789957Phase 3
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1cTerminatedNCT01785771Phase 3
- Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic DamageStatus unknownNCT01783717Not applicable
- Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic PatientsCompletedNCT01776788Phase 4
- SAFEGUARD: Pleiotropic Effects of Incretin Based TherapiesCompletedNCT01744236Phase 4
- DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R AgonistsCompletedNCT01575301Not applicable
- Pharmacology of Exenatide in Pediatric SepsisWithdrawnNCT01573806Phase 1/2
- Effects of the GLP-1 Exenatide on Satiety in Lean and Obese WomenCompletedNCT01501084Phase 1
- Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic PatientsCompletedNCT01473147Not applicable
- A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 DiabetesWithdrawnNCT01455922Phase 3
- A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 DiabetesWithdrawnNCT01455909Phase 3
- A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650CompletedNCT01455896Phase 3
- A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 DiabetesWithdrawnNCT01455883Phase 3
- A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 DiabetesCompletedNCT01455870Phase 3
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 DiabetesCompletedNCT01455857Phase 3
- Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 DiabetesStatus unknownNCT01435980Phase 4
- Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary BypassCompletedNCT01373216Phase 3
- GLP Analogs for Diabetes in Wolfram Syndrome PatientsWithdrawnNCT01302327Not applicable
- The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and DiabetesCompletedNCT01281228Not applicable
- The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic PatientsStatus unknownNCT01270191Phase 4
- Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial)Status unknownNCT01254123Phase 3
- Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes MellitusCompletedNCT01235819Phase 4
- Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH)CompletedNCT01208649Phase 4
- Exendin-4 as a Treatment for Parkinson's Disease - Pilot StudyStatus unknownNCT01174810Phase 2
- Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 DiabetesStatus unknownNCT01140893Phase 2/3
- Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes TreatmentCompletedNCT01076842Phase 4
- Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in HumansCompletedNCT01056549Not applicable
- Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its MechanismsCompletedNCT01046721Not applicable
- Effects of Exenatide on Postprandial Hyperlipidemia and InflammationCompletedNCT00974272Phase 4
- A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) ExenatideCompletedNCT00964262Phase 1
- The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 DiabetesCompletedNCT00950677Phase 4
- Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 DiabetesCompletedNCT00948168Phase 4